臨床婦人科産科78巻1号

2024年01月発行

合併増大号　今月の臨床 産婦人科医のための感染症最新レクチャー

各論 : 腫瘍学

HPVワクチンの有効性と副反応

著者： 笹川寿之¹ 柴田健雄¹ 坂本人一¹ 藤田智子¹ 高倉正博¹

所属機関： ¹金沢医科大学医学部産科婦人科学教室

ページ範囲：P.140 - P.147

文献概要

●HPVワクチンは，HPV16・18型などの高リスク型HPVの外郭蛋白であるL1が集合して構成されたウイルス様粒子を抗原に用いており，有効で安全な最新のワクチンである．

●本ワクチンの実際の効果は驚異的で，16歳までの女子に対する国民接種により，欧米のいずれの国でも，子宮頸がんおよびその前がん病変は9割近く減少している．

●本ワクチン接種直後の卒倒や2週間以内に起こる局所疼痛，発熱などの副反応は起こりうる．しかし，社会問題になった多彩な全身症状は一部の思春期女子に自然に発生するものであり，本ワクチンが直接の原因ではない．

参考文献

1）Gissmann L, et al : Presence of human papillomavirus in genital tumors. J Invest Dermatol 83（1suppl） : 26s-28s, 1984

2）Zhou J, et al : Expression of vaccinia recombinant HPV 16L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185 : 251-257, 1991

3）Kirnbauer R, et al : Efficient self-assembly of human papillomavirus type 16L1 and L1-L2 into virus-like particles. J Virol 67 : 6929-6936, 1993

4）Sasagawa T, et al : Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206 : 126-135, 1995

5）Hanley SJ, et al : HPV vaccination crisis in Japan. Lancet 385 : 2571, 2015

6）第94回厚生科学審議会予防接種・ワクチン分科会副反応検討部会，他 : 資料3-2　HPVワクチンの実施状況について．2023年7月28日．https://www.mhlw.go.jp/content/10601000/001126459.pdf

7）World Health Organization : Global strategy to accelerate the elimination of cervical cancer as a public health problem. Global strategy, WHO, 17 November, 2020

8）Mavrommatis E, et al : Historical pearls of HPV research : from condyloma to cervical cancer. Infez Med 29 : 278-283, 2021

9）Purzycka-Bohdan D, et al : The pathogenesis of giant condyloma acuminatum（Buschke-Lowenstein tumor） : an overview. Int J Mol Sci 23 : 4547, 2022

10）Brogaard KA, et al : Detection of oncogenic genital human papillomavirus（HPV）among HPV negative older and younger women after 7 years of follow-up. J Med Virol 86 : 975-982, 2014

11）Sasagawa T, et al : Immune responses against human papillomavirus（HPV）infection and evasion of host defense in cervical cancer. J Infect Chemother 18 : 807-815, 2012

12）Koutsky LA, et al : Proof of Principle Study Investigators : a controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 : 1645-1651, 2002

13）Sakamoto J, et al : Single type infection of human papillomavirus as a cause for high-grade cervical intraepithelial neoplasia and invasive cancer in Japan. Papillomavirus Res 6 : 46-51, 2018

14）Palmer T, et al : Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland : retrospective population study. BMJ 365 : l1161, 2019

15）Lei J, et al : HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 383 : 1340-1348, 2020

16）Falcaro M, et al : The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence : a register-based observational study. Lancet 398 : 2084-2092, 2021

17）Kudo R, et al : Effectiveness of human papillomavirus vaccine against cervical precancer in Japan : multivariate analyses adjusted for sexual activity. Cancer Sci 113 : 3211-3220, 2022

18）Onuki M, et al ; MINT Study Group : Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women. Cancer Sci 113 : 1428-1434, 2022

19）Bonanni P, et al : Efficactiveness, duration of immunity and cross protection after HPV vaccination : a review of the evidence. Vaccine 27（Suppl 1） : A46-A53, 2009

20）Saeki Y, et al : Effectiveness of prophylactic HPV vaccine for cervical abnormality and HPV infection in Japan : J-HERS-2021. J Med Virol 2023（in print）

21）Simms KT, et al : Impact of HPV vaccine hesitancy on cervical cancer in Japan : a modelling study. Lancet Public Health 5 : e223-e234, 2020

22）Sonawane K, et al : Trends in human papillomavirus vaccine safety concerns and adverse event reporting in the United States. JAMA Netw Open 4 : e2124502, 2021

23）Fukushima W, et al : A nationwide epidemiological survey of adolescent patients with diverse symptoms similar to those following human papillomavirus vaccination : background prevalence and incidence for considering vaccine safety in Japan. J Epidemiol 32 : 34-43, 2022

24）Matsumura N, et al : Scientific evaluation of alleged findings in HPV vaccines : Molecular mimicry and mouse models of vaccine-induced disease. Cancer Sci 113 : 3313-3320, 2022

25）Suzuki S, et al : No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women : results of the Nagoya study. Papillomavirus Res 5 : 96-103, 2018

26）Grimaldi-Bensouda L, et al ; PGRx-AD Study Group : Risk of autoimmune diseases and human papilloma virus（HPV） vaccines : six years of case-referent surveillance. J Autoimmun 79 : 84-90, 2017

27）Gee J, et al ; Vaccine Safety Datalink Team : Risk of Guillain-Barré syndrome following quadrivalent human papillomavirus vaccine in the vaccine safety datalink. Vaccine 35 : 5756-5758, 2017

28）Arana J, et al : Reports of postural orthostatic tachycardia syndrome after human papillomavirus vaccination in the vaccine adverse event reporting system. J Adolesc Health 61 : 577-582, 2017